Overexpression of the cell adhesion molecules DDR1, claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer

Clinical Cancer Research

Volumn 10, Issue 13, 2004, Pages 4427-4436

  Heinzelmann Schwarz, Viola A ^a   Gardiner Garden, Margaret ^a   Henshall, Susan M ^a   Scurry, James ^b   Scolyer, Richard A ^c   Davies, Michael J ^a   Heinzelmann, Matthias ^a   Kalish, Larry H ^a   Bali, Anish ^a   Kench, James G ^a   Edwards, Lyndal S ^b   Vanden Bergh, Patricia M ^a   Hacker, Neville F ^d   Sutherland, Robert L ^a   O'Brien, Philippa M ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d ROYAL HOSPITAL FOR WOMEN   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CLAUDIN; CLAUDIN 3; DISCOIDIN DOMAIN RECEPTOR 1; EPITHELIAL CELL ADHESION MOLECULE; MEMBRANE PROTEIN; RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CELLULAR DISTRIBUTION; EARLY DIAGNOSIS; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GYNECOLOGIC CANCER; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNINDEXED SEQUENCE;

ANTIGENS, NEOPLASM; CELL ADHESION; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MEMBRANE; COHORT STUDIES; DATABASES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA, COMPLEMENTARY; EPITHELIUM; FEMALE; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; OVARY; RECEPTOR PROTEIN-TYROSINE KINASES; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 3042736088     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0073     Document Type: Article

References (47)

1. Young RH, Scully RE. Differential diagnosis of ovarian tumors based primarily on their patterns and cell types. Semin Diagn Pathol 2001;18:161-235.
2. Ries LAG, Eisner MP, Kosary CL, KeinAutor M. SEER Cancer statistics review, 1975-2000. Bethesda, MD: National Cancer Institute; 2003.
3. Bast RCJ, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA125: the past and the future. Int J Biol Markers 1998;13:179-87.
4. Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization of an array of 21500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene (Amst.) 1999;238:375-85.
5. Wang K, Gan L, Jeffery E, et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene (Amst.) 1999;229:101-8.
6. Hough C, Sherman-Baust C, Pizer E, et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000;60:6281-7.
7. Ismail R, Baldwin R, Fang J, et al. Differential gene expression between normal and tumour-derived ovarian epithelial cells. Cancer Res 2000;60:6744-9.
8. Martoglio A, Tom B, Starkey M, Corps A, Charnock-Jones D, Smith S. Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays. Mol Med 2000;6:750-65.
9. Ono K, Tanaka T, Tsunoda T, et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 2000;60:5007-11.
10. Shridhar V, Lee J, Pandita A, et al. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res 2001;61:5895-904.
11. Tapper J, Kettunen E, El-Rifai W, Seppaelae M, Andersson LC, Knuutila S. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet 2001;128:1-6.
12. Tonin PN, Hudson TJ, Rodier F, et al. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene 2001;20:6617-26.
13. Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001;98:1176-81.
14. Bayani J, Brenton JD, Macgregor PF, et al. Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microassays. Cancer Res 2002;62:3466-76.
15. Matei D, Graeber T, Baldwin R, Karlan B, Rao J, Chang D. Gene expression in epithelial ovarian carcinoma. Oncogene 2002;21:6289-98.
16. Sawiris GP, Sherman-Baust CA, Becker KG, Cheadle C, Teichberg D, Morin PJ. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Cancer Res 2002;62:2923-8.
17. Vogel WF. Discoidin domain receptors: structural relations and functional implications. FASEB J 1999;13:S77-82.
18. Morita K, Furuse M, Fujimoto K, Tsukita S. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci USA 1999;96:511-6.
19. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999;77:699-712.
20. Auersperg N, Wong AST, Choi KC, Kang SK, Leung PCK. Ovarian surface epithelium: biology, endocrinology and pathology. Endocr Rev 2001;22:255-88.
21. Dong Y, Walsh MD, Cummings MC, et al. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J Pathol 1997;183:311-7.
22. Roskelley CD, Bissel MJ. The dominance of the microenvironment in breast and ovarian cancer. Cancer Biol 2002;12:97-104.
23. Henshall SM, Afar DE, Hiller J, et al. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 2003;63:4196-203.
24. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700.
25. Kim J, Skates S, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. J Am Med Assoc 2002;287:1671-9.
26. Simpson BJ, Weatherill J, Miller EP, Lessells AM, Langdon SP, Miller WR. c-erbB-3 protein expression in ovarian tumours. Br J Cancer 1995;71:758-62.
27. Shigemasa K, Tanimoto H, Underwood LJ, et al. Expression of the protease inhibitor antileukoprotease and the serine protease stratum corneum chymotryptic enzyme (SCCE) is coordinated in ovarian tumors. Int J Gynecol Cancer 2001;11:454-61.
28. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22:337-58.
29. Humbert P, Russell S, Richardson H. Dlg, Scribble and Lgl in cell polarity, cell proliferation and cancer. Bioessays 2003;25:542-53.
30. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607.
31. Pedersen I, Dervan P, Broderick D, et al. Frequent loss of imprinting of PEG1/MEST in invasive breast cancer. Cancer Res 1999;59:5449-51.
32. Eckel KL, Tentler JJ, Cappetta GJ, Diamond SE, Gutierrez-Hartmann A. The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression. DNA Cell Biol 2003;22:79-94.
33. Chen C, Bhalala H, Vessella R, Dong J. KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate 2003;55:81-8.
34. Chen C, Bhalala HV, Qiao H, Dong J-T. A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 2002;21:6567-72.
35. Katoh M. GIPC gene family [Review]. Int J Mol Med 2002;9:585-9.
36. Rangel LBA, Agarwahl R, D'Souza T, et al. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 2003;9:2567-75.
37. Mayerle J, Friess H, Buchler M, et al. Up-regulation, nuclear import, and tumor growth stimulation of the adhesion protein p120 in pancreatic cancer. Gastroenterology 2003;124:949-60.
38. Jawhari A, Noda M, Pignatelli M, Farthing M. Up-regulated cytoplasmic expression, with reduced membranous distribution, of the src substrate p120(ctn) in gastric carcinoma. J Pathol 1999;189:180-5.
39. Christofori G. Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression. EMBO J 2003;22(10):2318-23.
40. Vogel WF. Ligand-induced shedding of discoidin domain receptor 1. FEBS Lett 2002;514:175-80.
41. Singer G, Kurman RJ, Chang HW, Cho SK, Shih IM. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002;160:1223-8.
42. Darai E, Scoazec JY, Walker-Combrouze F, et al. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol 1997;28:922-8.
43. Sundfeldt K. Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Mol Cell Endocrinol 2003;202:89-96.
44. Haisma HJ, Pinedo HM, Rijswijk A, et al. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Ther 1999;6:1469-74.
45. Wimberger P, Xiang W, Mayr D, et al. Efficient tumor cell lysis by atologous, tumor-resident t-lymphocytes in primary ovarian cancer samples by an Ep-CAM-/CD3-bispecific antibody. Int J Cancer 2003;105:241-8.
46. Kim J, Herlyn D, Wong K, Park D, Schorge J, Lu K, Skates S, Cramer D, Berkowitz R, Mok S. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 2003;9:4782-91.
47. Weiner HL, Zagzag D. Growth factor receptor tyrosine kinases: cell adhesion kinase family suggests a novel signaling mechanism in cancer. Cancer Investig 2000;18:544-54.